Grünenthal uses its own and third-party cookies to improve the browsing experience, offer personalized content and improve its services. We use analytics scripts which set tracking cookies. More details and information can be found in our Data Privacy Statement – please refer to this to adjust your settings for website analytics tracking (e.g. enable/disable). By closing this window you agree to our standard Terms of Use.

I'm ok with this

Mechanisms and implications of placebo and nocebo responses in clinical trials – The 5th PainSolve Webinar | PainSolve
;

Updates & Features

Mechanisms and implications of placebo and nocebo responses in clinical trials – The 5th PainSolve Webinar

July 2019 

Strategies to minimise and harmonise placebo responses in clinical trials

PainSolve Editorial Team

Prof. Ulrike Bingel (University Hospital Essen, Germany) kindly hosted her 3rd and final placebo effect PainSolve webinar on the 13th June 2019, titled, ‘Mechanisms and implications of placebo and nocebo responses – focus on clinical trials’. Following on from her first two webinars on mechanisms of the placebo effect and its implications on clinical outcomes, Prof. Bingel presented data on ways that the placebo effect could be modulated during randomised control trials (RCTs).

Like
 
Share

Share this with:

These are external links and will open in a new window